Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily: Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)

BACKGROUND: In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325-fold more potent inhibition than imatinib against unmutated Bcr-Abl in vitro. Data wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Kantarjian, Hagop, Pasquini, Ricardo, Lévy, Vincent, Jootar, Saengsuree, Holowiecki, Jerzy, Hamerschlak, Nelson, Hughes, Timothy, Bleickardt, Eric, Dejardin, David, Cortes, Jorge, Shah, Neil P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345391/
https://ncbi.nlm.nih.gov/pubmed/19536906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24504
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados